Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Roku

Cathie Wood's Ark Innovation ETF has trounced the S&P 500 this year, and a couple of important components are expected to drive it even higher. Exact Sciences is a cancer diagnostics stock that could more than double by 2027 if it meets Ark Invest's expectations.

2 Supercharged Growth Stocks That Could Rocket 116% to 899% Higher, According to Wall Street

MADISON, Wis. , April 12, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research® (AACR) Annual Meeting 2023, April 14-19, in Orlando, Florida.

Exact Sciences Presents Advancements in Cancer Detection at American Association for Cancer Research® 2023 Annual Meeting

MADISON, Wis. , April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023.

Exact Sciences schedules first quarter 2023 earnings call

iCAD

It's certainly not easy to find millionaire-maker stocks if you only have $50,000 or less to invest. In order to turn that amount of money into $1 million using a single stock, you'll need vision, a contrary nature, tenacity, and a great deal of patience.

The 3 Best Millionaire-Maker Stocks to Buy for April 2023

Population-based cancer screening is now closer than ever to becoming a reality. EXAS products have a leading market position in their respective markets, offering a solid foundation as the company expands into new market opportunities.

Exact Sciences Leads The Way In Low-Cost Cancer Screening

Tesla

Oh, what A difference a year makes. Cathie Wood stocks in 2023 are doing so much better than the disaster in 2022.

3 Cathie Wood Stocks for Your April Must-Buy List

Intellia Therapeutics

UiPath

Shopify

Block

Teladoc

Twilio

Zoom Video

Cathie Wood (Catherine Duddy Wood) is the founder and CEO of ARK Invest. Before founding ARK Invest, Wood was with AllianceBernstein as Chief Investment Officer of Global Thematic Strategies.

These Are the Top 10 Holdings of Cathie Wood

Salesforce

Visa

Stocks with potential are probably not everyone's cup of tea right now. With talks of an impending recession, everyone is looking for safer options.

3 Stocks With Superior Potential for Super-Sized Gains in 2023

Moderna

Moderna is helping move the vaccine industry forward with its mRNA approach. Exact Sciences' products help patients and physicians better fight against cancer.

A Nasdaq Bull Market Is Coming: 2 Revolutionary Stocks to Buy and Hold

Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. The company's long-term prospects look interesting with a pipeline spread across different timelines, including a MCED test and MRD testing.

Exact Sciences' Shift In Strategy: Targeting Positive Adjusted EBITDA

C3.ai

Upstart Holdings

Love it or hate it, tech investing is back on the menu in 2023. As a result, Cathie Wood's back in the limelight.

Cathie Wood Is Betting Big on These 5 AI Stocks

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.

Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls

MADISON, Wis. , Feb. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Exact Sciences to participate in March investor conferences

Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET Company Participants Megan Jones - Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Jeff Elliott - Chief Financial Officer and Chief Operating Officer Everett Cunningham - Chief Commercial Officer Conference Call Participants Derik De Bruin - Bank of America Andrew Brackmann - William Blair Dan Brennan - Cowen Vijay Kumar - Evercore ISI Catherine Schulte - Baird Brandon Couillard - Jefferies Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Mark Massaro - BTIG Dan Arias - Stifel Puneet Souda - SVB Securities Patrick Donnelly - Citi Andrew Cooper - Raymond James Dan Leonard - Credit Suisse Operator Good morning. My name is Rob and I will be your conference operator today.

Exact Sciences Corporation (EXAS) Q4 2022 Earnings Call Transcript

Exact Sciences delivered a second consecutive quarter of sales growth acceleration Tuesday. The results could spark EXAS stock.

Exact Sciences, Which Outperforms 95% Of All Stocks, Just Beat Quarterly Estimates

Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter and 2022  highlights Total fourth quarter revenue of $553 million, an increase of 17% or 28% excluding COVID-19 testing, with Screening revenue of $404 million and Precision Oncology revenue of $143 million Total 2022 revenue of $2,084 million, an increase of 18% or 25% excluding COVID-19 testing, with Screening revenue of $1,425 million and Precision Oncology revenue of $601 million Surpassed 12 million cumulative people tested for cancer, including 10 million with Cologuard® MADISON, Wis. , Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.

Exact Sciences Announces Fourth Quarter 2022 Results

GFL Environmental

Lincoln Electric Hlds

NiSource

Teck Resources

The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.

5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week

Editas Medicine

Which of these rebounding biotech stocks is the better buy right now?

Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Exact Sciences (EXAS)

Today, we zero in on Exact Sciences Corporation, best known for its "best of breed" non-invasive stool-based DNA screening test called Cologuard. Exact Sciences stock has soared 35% so far in 2023 thanks largely to an upward revision to fourth quarter guidance.

Exact Sciences Corporation: Fully Priced After Big Rally

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average

Integra LifeSciences Holdings

Medtronic

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

Are these stocks still good buys right now?

3 Growth Stocks That Are Off to Hot Starts in 2023

Test Identifies Tumor DNA and RNA Alterations to Help Guide Personalized Treatments for Patients Based on Their Cancer MADISON, Wis. , Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection test in the United States.

News for Exact Sciences Stock (EXAS)